Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia

Nature Cell Biology

Volumn 14, Issue 3, 2012, Pages 276-286

  Zhang, Wan ^a,b   Trachootham, Dunyaporn ^a,c   Liu, Jinyun ^a,d   Chen, Gang ^a   Pelicano, Helene ^a   Garcia Prieto, Celia ^a   Lu, Weiqin ^a   Burger, Jan A ^a   Croce, Carlo M ^e   Plunkett, William ^a   Keating, Michael J ^a   Huang, Peng ^a,d  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NANCHANG UNIVERSITY   (China)

^c THAMMASAT UNIVERSITY   (Thailand)

^d UNIVERSITY OF TEXAS   (United States)

^e THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 CARBOXYPHENYLGLYCINE; CYSTEINE; CYSTINE; FLUDARABINE; GLUTATHIONE; OXALIPLATIN; PHENETHYL ISOTHIOCYANATE; REACTIVE OXYGEN METABOLITE; SALAZOSULFAPYRIDINE;

AMINO ACID METABOLISM; AMINO ACID TRANSPORT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER RESISTANCE; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SENSITIVITY; GLUTATHIONE METABOLISM; HUMAN; HUMAN CELL; LEUKEMIA CELL; MOUSE; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PRIORITY JOURNAL; STROMA CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; BONE MARROW CELLS; CELL COMMUNICATION; CELL LINE; CELL SURVIVAL; COCULTURE TECHNIQUES; CULTURE MEDIA, CONDITIONED; CYSTEINE; CYSTINE; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; GLUTATHIONE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MOLECULAR WEIGHT; ORGANOPLATINUM COMPOUNDS; REACTIVE OXYGEN SPECIES; STROMAL CELLS; TUMOR CELLS, CULTURED; VIDARABINE;

EID: 84862777168     PISSN: 14657392     EISSN: 14764679     Source Type: Journal    
DOI: 10.1038/ncb2432     Document Type: Article

References (62)

1. Zwiebel, J. A. & Cheson, B. D. Chronic lymphocytic leukemia: staging and prognostic factors. Semin. Oncol. 25, 42-59 (1998). (Pubitemid 28090911)
2. Keating, M. J. et al. Biology and treatment of chronic lymphocytic leukemia. Hematology/the Education Program of the American Society of Hematology. Am. Soc. Hematol. 153-175 (2003).
3. Chiorazzi, N., Rai, K. R. & Ferrarini, M. Chronic lymphocytic leukemia. New Engl. J. Med. 352, 804-815 (2005).
4. Tam, C. S. & Keating, M. J. Chemoimmunotherapy of chronic lymphocytic leukemia. Best Practice Res. 20, 479-498 (2007). (Pubitemid 47263407)
5. Rai, K. R. & Chiorazzi, N. Determining the clinical course and outcome in chronic lymphocytic leukemia. New Engl. J. Med. 348, 1797-1799 (2003). (Pubitemid 36514711)
6. Collins, R. J. et al. Spontaneous programmed death (apoptosis) of B-chronic lymphocytic leukaemia cells following their culture in vitro. Br. J. Haematol. 71, 343-350 (1989). (Pubitemid 19086646)
7. Munk Pedersen, I. & Reed, J. Microenvironmental interactions and survival of CLL B-cells. Leuk. Lymphoma 45, 2365-2372 (2004). (Pubitemid 40081179)
8. Lagneaux, L., Delforge, A., Bron, D., De Bruyn, C. & Stryckmans, P. Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells. Blood 91, 2387-2396 (1998).
9. Grdisa, M. Influence of CD40 ligation on survival and apoptosis of B-CLL cells in vitro. Leuk. Res. 27, 951-956 (2003). (Pubitemid 36809092)
10. Dancescu, M. et al. Interleukin 4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates Bcl-2 expression. J. Exp. Med. 176, 1319-1326 (1992).
11. Jewell, A. P. et al. Inte-rferon-α up-regulates bcl-2 expression and protects B-CLL cells from apoptosis in vitro and in vivo. Br. J. Haematol. 88, 268-274 (1994).
12. Buschle, M. et al. Inte-rferon inhibits apoptotic cell death in B cell chronic lymphocytic leukemia. J. Exp. Med. 177, 213-218 (1993).
13. Konig, A. et al. BasicκBroblast growth factor (bFGF) upregulates the expression of bcl-2 in B cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis. Leukemia 11, 258-265 (1997). (Pubitemid 27085171)
14. Burger, J. A. et al. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 96, 2655-2663 (2000).
15. Endo, T. et al. BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-κB pathway. Blood 109, 703-710 (2007). (Pubitemid 46105972)
16. Hegde, G. V. et al. Hedgehog-induced survival of B-cell chronic lymphocytic leukemia cells in a stromal cell microenvironment: a potential new therapeutic target. Mol. Cancer Res. 6, 1928-1936 (2008).
17. Lawton, K. A. et al. Analysis of the adult human plasma metabolome. Pharmacogenomics 9, 383-397 (2008). (Pubitemid 351803924)
18. Sreekumar, A. et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457, 910-914 (2009).
19. Dang, L. et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 465, 966 (2010).
20. Zhou, Y., Hileman, E. O., Plunkett, W., Keating, M. J. & Huang, P. Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents. Blood 101, 4098-4104 (2003). (Pubitemid 36857891)
21. Oltra, A. M., Carbonell, F., Tormos, C., Iradi, A. & Saez, G. T. Antioxidant enzyme activities and the production of MDA and 8-oxo-dG in chronic lymphocytic leukemia. Free Radic. Biol. Med. 30, 1286-1292 (2001). (Pubitemid 32463939)
22. Carew, J. S. et al. Mitochondrial DNA mutations in primary leukemia cells after chemotherapy: clinical significance and therapeutic implications. Leukemia 17, 1437-1447 (2003). (Pubitemid 36986944)
23. Trachootham, D. et al. Effective elimination offludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism. Blood 112, 1912-1922 (2008).
24. Silber, R. et al. Glutathione depletion in chronic lymphocytic leukemia B lymphocytes. Blood 80, 2038-2043 (1992).
25. Hileman, E. O., Liu, J., Albitar, M., Keating, M. J. & Huang, P. Intrinsic oxidative stress in cancer cells: a biochemical basis for therapeutic selectivity. Cancer Chemother. Pharmacol. 53, 209-219 (2004). (Pubitemid 38293718)
26. Kurtova, A. V. et al. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood 114, 4441-4450 (2009).
27. Woodlock, T. J. et al. Decreased L system amino acid transport and decreased-glutamyl transpeptidase are independent processes in human chronic lymphocytic leukemia B-lymphocytes. J. Cell Physiol. 145, 217-221 (1990). (Pubitemid 120027355)
28. Trachootham, D. et al. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by β-phenylethyl isothiocyanate. Cancer Cell. 10, 241-252 (2006). (Pubitemid 44311067)
29. Lu, S. C. Regulation of glutathione synthesis. Curr. Top. Cell. Regul. 36, 95-116 (2000).
30. Jones, D. P. & Liang, Y. Measuring the poise of thiol/disulfide couples in vivo. Free Radic. Biol. Med. 47, 1329-1338 (2009).
31. Sato, H. et al. Redox imbalance in cystine/glutamate transporter- deficient mice. J. Biol. Chem. 280, 37423-37429 (2005). (Pubitemid 41642349)
32. Haslinger, C. et al. Microarray gene expression profiling of B-cell chronic lymphocytic leukemia subgroups defined by genomic aberrations and VH mutation status. J. Clin. Oncol. 22, 3937-3949 (2004). (Pubitemid 41079876)
33. Zenz, T. et al. Detailed analysis of p53 pathway defects infludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood 114, 2589-2597 (2009).
34. Turgut, B. et al. 17p Deletion is associated with resistance of B-cell chronic lymphocytic leukemia cells to in vitrofludarabine-induced apoptosis. Leuk. Lymphoma 48, 311-320 (2007). (Pubitemid 46994881)
35. Huang, Y., Dai, Z., Barbacioru, C. & Sadee, W. Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance. Cancer Res. 65, 7446-7454 (2005). (Pubitemid 41161279)
36. Gout, P. W., Buckley, A. R., Simms, C. R. & Bruchovsky, N. Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c)-cystine transporter: a new action for an old drug. Leukemia 15, 1633-1640 (2001). (Pubitemid 32994684)
37. Moufarij, M. A., Sampath, D., Keating, M. J. & Plunkett, W. Fludarabine increases oxaliplatin cytotoxicity in normal and chronic lymphocytic leukemia lymphocytes by suppressing interstrand DNA crosslink removal. Blood 108, 4187-4193 (2006). (Pubitemid 44913291)
38. Graham, M. A. et al. Clinical pharmacokinetics of oxaliplatin: a critical review. Clin. Cancer Res. 6, 1205-1218 (2000). (Pubitemid 30226200)
39. Danhauser, L., Plunkett, W., Keating, M. & Cabanillas, F. 9-β-D-arabinofuranosyl-2-fluoroadenine 50-monophosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphoma. Cancer Chemother. Pharmacol. 18, 145-152 (1986). (Pubitemid 17121429)
40. Bichi, R. et al. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc. Natl Acad. Sci. USA 99, 6955-6960 (2002). (Pubitemid 34526239)
41. Reed, J. C. Molecular biology of chronic lymphocytic leukemia. Semin. Oncol. 25, 11-18 (1998). (Pubitemid 28090907)
42. Caligaris-Cappio, F. Biology of chronic lymphocytic leukemia. Rev. Clin. Exp. Hematol. 4, 5-21 (2000). (Pubitemid 34947476)
43. Bannai, S. Transport of cystine and cysteine in mammalian cells. Biochim. Biophys. Acta 779, 289-306 (1984). (Pubitemid 14027591)
44. Iglehart, J. K., York, R. M., Modest, A. P., Lazarus, H. & Livingston, D. M. Cystine requirement of continuous human lymphoid cell lines of normal and leukemic origin. J. Biol. Chem. 252, 7184-7191 (1977). (Pubitemid 8206272)
45. Uren, J. R. & Lazarus, H. L-cyst(e)ine requirements of malignant cells and progress toward depletion therapy. Cancer Treatment Rep. 63, 1073-1079 (1979). (Pubitemid 10220107)
46. Hyde, R., Taylor, P. M. & Hundal, H. S. Amino acid transporters: roles in amino acid sensing and signalling in animal cells. Biochem. J. 373, 1-18 (2003). (Pubitemid 36819495)
47. Liu, R. et al. Cystine-glutamate transporter SLC7A11 mediates resistance to geldanamycin but not to 17-(allylamino)-17-demethoxygeldanamycin. Mol. Pharm. 72, 1637-1646 (2007). (Pubitemid 350146101)
48. Lo, M., Wang, Y. Z. & Gout, P. W. The x(c)-cystine/glutamate antiporter: a potential target for therapy of cancer and other diseases. J. Cell. Physiol. 215, 593-602 (2008). (Pubitemid 351632680)
49. Okuno, S. et al. Role of cystine transport in intracellular glutathione level and cisplatin resistance in human ovarian cancer cell lines. Br. J. Cancer 88, 951-956 (2003). (Pubitemid 36520886)
50. Chawla, R. K. et al. Plasma cysteine, cystine, and glutathione in cirrhosis. Gastroenterology 87, 770-776 (1984). (Pubitemid 14040447)
51. Lu, S. C. Regulation of glutathione synthesis. Mol. Aspects Med. 30, 42-59 (2009).
52. Franco, R., Panayiotidis, M. I. & Cidlowski, J. A. Glutathione depletion is necessary for apoptosis in lymphoid cells independent of reactive oxygen species formation. J. Biol. Chem. 282, 30452-30465 (2007). (Pubitemid 350035221)
53. Franco, R., DeHaven, W. I., Sifre, M. I., Bortner, C. D. & Cidlowski, J. A. Glutathione depletion and disruption of intracellular ionic homeostasis regulate lymphoid cell apoptosis. J. Biol. Chem. 283, 36071-36087 (2008).
54. Tew, K. D. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res. 54, 4313-4320 (1994). (Pubitemid 24273141)
55. Kelland, L. The resurgence of platinum-based cancer chemotherapy. Nat. Rev. 7, 573-584 (2007). (Pubitemid 47106628)
56. Roecklein, B. A. & Torok-Storb, B. Functionally distinct human marrow stromal cell lines immortalized by transduction with the human papilloma virus E6/E7 genes. Blood 85, 997-1005 (1995).
57. Kawano, Y. et al. Ex vivo expansion of human umbilical cord hematopoietic progenitor cells using a coculture system with human telomerase catalytic subunit (hTERT)-transfected human stromal cells. Blood 101, 532-540 (2003). (Pubitemid 36077574)
58. Matsumoto, S. et al. Membranous osteogenesis system modeled with KUSA-A1 mature osteoblasts. Biochim. Biophys. Acta 1725, 57-63 (2005). (Pubitemid 41174535)
59. Huang, P., Sandoval, A., Van Den Neste, E., Keating, M. J. & Plunkett, W. Inhibition of RNA transcription: a biochemical mechanism of action against chronic lymphocytic leukemia cells byfludarabine. Leukemia 14, 1405-1413 (2000). (Pubitemid 30599321)
60. Pelicano, H. et al. Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism. J. Biol. Chem. 278, 37832-37839 (2003). (Pubitemid 37175311)
61. Pepper, C., Thomas, A., Hoy, T., Fegan, C. & Bentley, P. Flavopiridol circumvents Bcl-2 family mediated inhibition of apoptosis and drug resistance in B-cell chronic lymphocytic leukaemia. Br. J. Haematol. 114, 70-77 (2001). (Pubitemid 32702635)
62. Campas, C. et al. Prodigiosin induces apoptosis of B and T cells from B-cell chronic lymphocytic leukemia. Leukemia 17, 746-750 (2003). (Pubitemid 36519371)